A Population-Based Analysis of the Frequency of Anemia and Its Management before and during Chemotherapy in Patients with Malignant Lymphoma.
Notice bibliographique
Résumé
Abstract In patients with hematologic malignancies, chemotherapy has the potential to further suppress bone marrow production. While measures to correct anemia including transfusion and growth factor support can improve patients’ function and quality of life, the intervention threshold and the methods of correcting anemia among clinicians managing patients with malignant lymphoma are not clear. The present study evaluates the frequency, severity and corrective interventions for anemia used before and during the delivery of the four most common chemotherapeutic regimens used at the BC Cancer Agency to treat patients with Hodgkin’s and Non-Hodgkin’s Lymphoma. A retrospective, electronic chart review was conducted of 316 patients who received cytotoxic chemotherapy for lymphoma at four BC Cancer Agency centers from June 1, 2004 to December 31, 2005. Initial hemoglobin (Hgb) and dates of first Hgb in the ranges, 110–119g/L, 100–109g/L, 90–99g/L and <90g/L were recorded. Review of medical records was performed to document the frequency of anemia-associated symptoms including fatigue and the frequency of any discussion or delivery of interventions for anemia (transfusion, epoetin [EPO] or both). In this study cohort, 23% of patients had Hodgkin’s and 77% had Non-Hodgkin’s disease. The proportions of male and female patients were 55% and 45%, respectively. The chemotherapy regimens delivered were: Doxorubicin, Cyclophosphamide, Vincristine and Prednisone (CHOP) in 24 patients, CHOP + Rituximab (CHOP-R) in 215 patients, Adriamycin, Bleomycin, Vinblastine, Dacarbazine (ABVD) in 73 patients, and Gemcitabine, Dexamethasone and Cisplatin (GDP) in 4 patients. Median age was 57 years (range 16–87 years). Prior to starting chemotherapy, 33% of subjects had a Hgb<120g/L and 7% subjects had a Hgb <100g/L. In patients with Hgb <100g/L prior to chemotherapy, fatigue was documented in 67% but intervention for Hgb <100g/L pre-chemotherapy occurred in only 10% of patients. Overall (before and during chemotherapy), the proportion of subjects with at least one Hgb<120g/L was 67%, <110g/L was 41%, <100g/L was 23% and <90g/L was 10%. Table 1 summarized anemia-related symptoms and interventions during chemotherapy delivery. Discussion and intervention rates increased as Hb declined, particularly at levels <90g/L. Among 32 patients with Hgb<90g/L, symptoms were documented in 23 patients. Transfusion was used in 23 patients and EPO was used in 1 patient. In conclusion, anemia was relatively common prior to and during chemotherapy for patients with malignant lymphoma. The threshold of anemia intervention during chemotherapy was Hgb <90g/L with transfusion as the predominant method used. Pre-chemotherapy intervention rates for anemia were low even in the presence of symptoms and at Hgb values where randomized trials have shown that intervention can improve fatigue and quality of life. Anemia-related symptoms and interventions during chemotherapy for patients with malignant lymphoma Hgb Range (g/L) Number of cases Symptoms Present Interventions Discussed but Not Given Transfusion Only EPO only Both Transfusion and EPO 110–119 137 21 0 0 0 0 100–109 96 31 1 0 0 0 90–99 59 27 7 4 0 0 <90 32 23 0 23 1 0
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,003 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,001 | 0,002 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,001 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».